發送短信 : Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE study

  ______    ______    ______    _____    _____    
 /_   _//  /_   _//  /_____//  |  ___|| |  __ \\  
   | ||     -| ||-   `____ `   | ||__   | |  \ || 
  _| ||     _| ||_   /___//    | ||__   | |__/ || 
 /__//     /_____//  `__ `     |_____|| |_____//  
 `--`      `-----`   /_//      `-----`   -----`   
                     `-`